- Home
- PHAR vs IAUX Comparison
PHAR vs IAUX Comparison
Compare PHAR & IAUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHAR
- IAUX
- Stock Information
- Founded
- PHAR 1988
- IAUX 2020
- Country
- PHAR Netherlands
- IAUX United States
- Employees
- PHAR N/A
- IAUX N/A
- Industry
- PHAR Biotechnology: Pharmaceutical Preparations
- IAUX
- Sector
- PHAR Health Care
- IAUX
- Exchange
- PHAR Nasdaq
- IAUX Nasdaq
- Market Cap
- PHAR 951.7M
- IAUX 889.5M
- IPO Year
- PHAR N/A
- IAUX N/A
- Fundamental
- Price
- PHAR $13.18
- IAUX $0.89
- Analyst Decision
- PHAR Strong Buy
- IAUX Buy
- Analyst Count
- PHAR 3
- IAUX 1
- Target Price
- PHAR $30.00
- IAUX $1.50
- AVG Volume (30 Days)
- PHAR 9.7K
- IAUX 6.0M
- Earning Date
- PHAR 11-06-2025
- IAUX 11-12-2025
- Dividend Yield
- PHAR N/A
- IAUX N/A
- EPS Growth
- PHAR N/A
- IAUX N/A
- EPS
- PHAR N/A
- IAUX N/A
- Revenue
- PHAR $339,836,000.00
- IAUX $76,622,000.00
- Revenue This Year
- PHAR $17.70
- IAUX $81.79
- Revenue Next Year
- PHAR $12.25
- IAUX $98.01
- P/E Ratio
- PHAR N/A
- IAUX N/A
- Revenue Growth
- PHAR 22.44
- IAUX 40.21
- 52 Week Low
- PHAR $7.31
- IAUX $0.34
- 52 Week High
- PHAR $17.08
- IAUX $1.15
- Technical
- Relative Strength Index (RSI)
- PHAR 43.85
- IAUX 41.74
- Support Level
- PHAR $13.03
- IAUX $0.93
- Resistance Level
- PHAR $13.43
- IAUX $0.99
- Average True Range (ATR)
- PHAR 0.49
- IAUX 0.06
- MACD
- PHAR -0.10
- IAUX -0.02
- Stochastic Oscillator
- PHAR 23.47
- IAUX 0.90
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.
About IAUX i-80 Gold Corp.
i-80 Gold Corp is a well-financed gold and silver producer engaged in the exploration, development, and production of gold, silver, and poly-metallic deposits. The Company's principal assets include the Ruby Hill Mine, Lone Tree Mine, Granite Creek Mine, and McCoy-Cove Project.